This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
26 Sep 2011

Isis Files Patent Infringement Suit Against Santaris

Isis' infringement suit against Santaris is based upon Santaris' activities providing antisense drugs and antisense drug discovery services to several pharmaceutical companies.

Biomedical pharmaceutical company Isis Pharmaceuticals has filed a patent infringement lawsuit against Santaris Pharma A/S and Santaris Pharma A/S Corp. in the United States District Court of the Southern District of California.

 

Isis' infringement suit against Santaris is based upon Santaris' activities providing antisense drugs and antisense drug discovery services to several pharmaceutical companies. As alleged in the complaint, these activities are not protected under the exemption from patent infringement for drug development.

 

In the filed complaint, Isis alleges infringement of U.S. Patent No. 6,326,199, entitled "Gapped 2' Modified Oligonucleotides" and U.S. Patent No. 6,066,500, entitle

Related News